Greggs back in fashion and Sirius Minerals soars on new development plan

“As we approach mid-November, the FTSE 100 is on track to record the best annual performance since 2016 despite a backdrop of economic concerns, trade...

Mon, 11/11/2019 - 10:34


Broker Forecast - Jefferies International issues a broker note on Ferguson Plc

Jefferies International today reaffirms its buy investment rating on Ferguson Plc (LON:FERG) and raised its price target to 7532p (from 7281p).

Broker Forecasts data provided...

Mon, 11/11/2019 - 10:30


Broker Forecast - Goldman Sachs issues a broker note on Rolls-Royce Group PLC

Goldman Sachs today reaffirms its conviction buy investment rating on Rolls-Royce Group PLC (LON:RR.) and cut its price target to 1143p (from 1196p).

Broker Forecasts...

Mon, 11/11/2019 - 10:20


Broker Forecast - Societe Generale issues a broker note on Rolls-Royce Group PLC

Societe Generale today downgrades its investment rating on Rolls-Royce Group PLC (LON:RR.) to hold (from buy) and cut its price target to 825p (from 930p)....

Mon, 11/11/2019 - 10:10


Agronomics confirms plans to raise up to £20m through equity placing

Agronomics confirmed that plans to raise up to £20m through an equity placing.

The company said it intended to price the placing shares at...

Mon, 11/11/2019 - 10:07


Hardide granted UK patent amid going development of steam and gas turbine blades

Surface coating technology maker Hardide said it had been granted a patent by the UK intellectual property office covering a water droplet erosion resistant coating...

Mon, 11/11/2019 - 10:03


AFH sees earnings, revenue above prior year

Wealth management firm AFH said it expected revenue and earnings to rise on-year, driven by new business.

Underlying earnings (EBITDA) were expected to exceed...

Mon, 11/11/2019 - 10:00


Broker Forecast - UBS issues a broker note on Rolls-Royce Group PLC

UBS today reaffirms its buy investment rating on Rolls-Royce Group PLC (LON:RR.) and cut its price target to 950p (from 1000p).

Broker Forecasts data provided...

Mon, 11/11/2019 - 10:00


Mereo BioPharma trial of bone condition treatment fails to reach primary goal

Mereo BioPharma said a clinical trial for its treatment for bone disorder osteogenesis imperfecta failed to achieve its primary endpoint of increasing bone density in...

Mon, 11/11/2019 - 09:56


Abcam agrees to acquire Expedeon's proteomics and immunology business for €120m

Abcam said it had agreed to acquire Expedeon's proteomics and immunology business for €120m in an effort to expand expanding offerings into the fast-growing conjugation...

Mon, 11/11/2019 - 09:55


Pages